- Home
- PLX vs FOSL Comparison
PLX vs FOSL Comparison
Compare PLX & FOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- FOSL
- Stock Information
- Founded
- PLX 1993
- FOSL 1984
- Country
- PLX United States
- FOSL United States
- Employees
- PLX N/A
- FOSL N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- FOSL Consumer Specialties
- Sector
- PLX Health Care
- FOSL Consumer Discretionary
- Exchange
- PLX Nasdaq
- FOSL Nasdaq
- Market Cap
- PLX 122.6M
- FOSL 100.0M
- IPO Year
- PLX 1998
- FOSL 1993
- Fundamental
- Price
- PLX $1.37
- FOSL $1.62
- Analyst Decision
- PLX Strong Buy
- FOSL Strong Buy
- Analyst Count
- PLX 1
- FOSL 1
- Target Price
- PLX $15.00
- FOSL $5.00
- AVG Volume (30 Days)
- PLX 1.3M
- FOSL 211.3K
- Earning Date
- PLX 08-13-2025
- FOSL 08-07-2025
- Dividend Yield
- PLX N/A
- FOSL N/A
- EPS Growth
- PLX N/A
- FOSL N/A
- EPS
- PLX 0.05
- FOSL N/A
- Revenue
- PLX $59,764,000.00
- FOSL $1,123,399,000.00
- Revenue This Year
- PLX $65.02
- FOSL N/A
- Revenue Next Year
- PLX $57.34
- FOSL N/A
- P/E Ratio
- PLX $28.34
- FOSL N/A
- Revenue Growth
- PLX 0.18
- FOSL N/A
- 52 Week Low
- PLX $0.82
- FOSL $0.86
- 52 Week High
- PLX $3.10
- FOSL $2.61
- Technical
- Relative Strength Index (RSI)
- PLX 41.78
- FOSL 59.00
- Support Level
- PLX $1.43
- FOSL $1.55
- Resistance Level
- PLX $1.54
- FOSL $1.80
- Average True Range (ATR)
- PLX 0.09
- FOSL 0.11
- MACD
- PLX 0.01
- FOSL 0.01
- Stochastic Oscillator
- PLX 5.77
- FOSL 71.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About FOSL Fossil Group Inc.
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.